GlassScriptPhysician profile
Roopa M Korni
NPI 1629272810
$9,070.23
in general payments reported to CMS, 2019-2025
28 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $624 · 2021: $1,194 · 2022: $1,519 · 2023: $1,499 · 2024: $1,564 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,433.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,674.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,369.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,264.04 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $768.36 | 2019-2025 | |
| Lilly USA, LLC | $592.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $529.88 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $467.58 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $369.16 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $247.36 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $217.63 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.90 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.69 | 2019-2024 | Jardiance, Tradjenta |
| Abbott Laboratories | $144.57 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $137.41 | 2022 | |
| Phathom Pharmaceuticals, INC. | $131.61 | 2023-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $131.50 | 2022-2025 | Livalo, Seglentis, Zoryve |
| Exact Sciences Corporation | $124.38 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $116.90 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $109.15 | 2019-2021 | |
| Allergan, INC. | $57.68 | 2019-2020 | |
| Alkermes, INC. | $51.30 | 2021-2022 | |
| Esperion Therapeutics, INC. | $43.93 | 2020-2022 | |
| Alk-Abello, INC | $29.03 | 2024 | Grastek, Ragwitek, Odactra |
| Amarin Pharma, INC. | $28.08 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $22.13 | 2021 | |
| Lundbeck LLC | $19.86 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $18.35 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.22 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopa Korni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.